Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Epic Medical Research

Neither a doctor nor a teaching hospital

Research payments

$27,524,977

5,508 payments

Through program year 2025, Epic Medical Research is reported as receiving $27,524,977 in research payments, across 5,508 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,609,423 291
2024 Research $6,723,655 242
2023 Research $4,230,303 2,038
2022 Research $4,411,862 2,811
2021 Research $9,419,253 118
2020 Research $1,125,231 6
2019 Research $5,250 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $11,747,475 998 payments
  2. Moderna TX, Inc. $7,151,003 3,958 payments
  3. Novartis Pharmaceuticals Corporation $1,613,451 8 payments
  4. Eli Lilly and Company $1,567,402 43 payments
  5. AstraZeneca Pharmaceuticals LP $1,045,962 24 payments
  6. AbbVie, Inc. $980,312 89 payments
  7. Braintree Laboratories, Inc. $868,345 33 payments
  8. LivaNova USA, Inc. $687,158 163 payments
  9. Pfizer Inc. $559,554 52 payments
  10. GlaxoSmithKline, LLC. $458,519 100 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 $5,844,007 61 payments
  2. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 $4,430,353 79 payments
  3. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $2,139,348 1,633 payments
  4. A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age $1,602,477 260 payments
  5. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $1,298,681 103 payments
  6. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $1,251,681 1,936 payments
  7. A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection $820,818 30 payments
  8. A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older $807,915 16 payments
  9. A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele $658,818 6 payments
  10. Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) $652,297 828 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record